Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Modex Therapeutics Inc. is currently managing a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are distributed among 2 distinct examiners, yet they are both contained within 1 distinct art unit. This suggests that while the company is interacting with different individuals, the procedural standards remain consistent across a single art unit.
GARY B NICKOL is identified as the busiest examiner for the company, with 1 busiest examiner pending office action. Given that there are 2 pending office actions in total, GARY B NICKOL is responsible for 1 of these active matters. The other pending action is handled by the other of the 2 distinct examiners.
For practitioners, this distribution offers a unique perspective. Although there are 2 distinct examiners to manage, the fact that they both operate within 1 distinct art unit means that the overarching policy and technological focus remain uniform. Strategy can be adapted to the individual styles of the 2 examiners while maintaining a consistent approach to the standards of the Biotechnology & Pharmaceuticals art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICKOL, GARY B | 1 | 47.1% | +31.1% |
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17936044 | ANTIGEN BINDING POLYPEPTIDES, ANTIGEN BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | DUFFY, BRADLEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17936041 | ANTIGEN BINDING POLYPEPTIDES, ANTIGEN BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | NICKOL, GARY B | — |
| 17936044 | ANTIGEN BINDING POLYPEPTIDES, ANTIGEN BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | DUFFY, BRADLEY | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17936041 | ANTIGEN BINDING POLYPEPTIDES, ANTIGEN BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | NICKOL, GARY B | 1643 | §112DP | Non-Final OA | — | Pending | Sep 28, 2022 |
| 17936044 | ANTIGEN BINDING POLYPEPTIDES, ANTIGEN BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | DUFFY, BRADLEY | 1643 | §102§112 | Non-Final OA | — | Pending | Sep 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial